CPhI Aims for Russia - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

CPhI Aims for Russia


In 2011, the organisers of CPhI, UMB Live, announced their intention to explore the US via the launch of ICSE USA. This year, the organisers are once again setting their sights on new territory, this time in Russia.

CPhI Russia is due to take place in Russia’s St Petersburg at the Manege Central Exhibition Hall on 10–11 April 2013, alongside the IPhEB event, which is a key event in Russia for the pharmaceutical, biotechnological and medical industry. In a statement, UBM Live said that it had actively sought a partnership with RESTEC, the organiser of IPhEB, to facilitate access to the Russian market.

“The Russian pharmaceutical market is set for tremendous growth: this year we already have seen leading pharmaceutical companies, such as Novartis and AstraZeneca, opening manufacturing sites and R&D centres in the St. Petersburg region and other parts of Russia. We believe our industry leading face-to-face events and digital products can play a critical role in accelerating that growth and driving innovation in the Russian pharmaceutical market," Andrew Pert, brand director for CPhI Russia, said in a statement.

According to a survey conducted by UBM Live of visitors to CPhI Worldwide 2011, held in Frankfurt, 42% of attendees were already active in the Russian pharmaceutical market. More than one third also had plans to enter the market during the next two years.

Russia is currently the eleventh largest pharmaceutical market in the world and is projected to reach a value of $26.7 billion by the end of 2013.

You can find out more about CPhI Russia and register your interest here.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here